Three of the world’s largest pharmaceutical firms are dashing to develop a drug that mimics the effects of an exceedingly rare genetic mutation that causes LDL cholesterol levels to be dramatically low, writes Gina Kolata, of the New York Times.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in Nature

Natural Knockouts

Human Knockouts

This Week in Cell

IQ Testing at Birth?

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.